<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00702754</url>
  </required_header>
  <id_info>
    <org_study_id>401CDNA</org_study_id>
    <secondary_id>401CDNA</secondary_id>
    <nct_id>NCT00702754</nct_id>
  </id_info>
  <brief_title>An Open Label Safety and Immunogenicity Study of MYOBLOC (Neurobloc; Botulinum Toxin Type B) Injectable Solution in Patients With Cervical Dystonia</brief_title>
  <official_title>An Open Label Safety and Immunogenicity Study of MYOBLOC (Neurobloc; Botulinum Toxin Type B) Injectable Solution in Patients With Cervical Dystonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Solstice Neurosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Solstice Neurosciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Five hundred patients with a confirmed clinical diagnosis of Cervical Dystonia (CD)are
      planned for enrollment into this open label study. These patients will be Type B toxin naive
      patients with CD. During this study patients will receive repeat injections of MYOBLOC when
      deemed appropriate by the Investigator. However, it will be recommended that injections occur
      not more frequently than every 12 weeks. Total duration of exposure to MYOBLOC will be
      targeted for at least two years, with potential exposure for up to 7 years in patients with
      earliest enrollment
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2001</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Assessment Scale (TAS), 4 Wks Post-injection Compared to Baseline (Time 0), Rating of Cervical Dystonia Symptoms</measure>
    <time_frame>Session 1 - Time 0, 4 weeks post-injection compared to baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment Assessment Scale (TAS), Approx Wk 12 + 4 Wks Post-Injection Compared to Baseline. Rating of Cervical Dystonia Symptoms</measure>
    <time_frame>Session 2 (12 wks) - 4 weeks post-injection compared to baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Assessment Scale (TAS), Approx Wk 24 + 4 Wks Post-injection Compared to Baseline. Rating of Cervical Dystonia Symptoms</measure>
    <time_frame>Session 3 (24 Wks) - 4 weeks post-injection compared to baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Assessment Scale (TAS), Approx Wk 36 + 4 Wks Post-injection Compared to Baseline. Rating of Cervical Dystonia Symptoms</measure>
    <time_frame>Session 4 (36 Wks) - 4 weeks post-injection compared to baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Assessment Scale (TAS), Approx Wk 48 + 4 Wks Post-injection Compared to Baseline. Rating of Cervical Dystonia Symptoms</measure>
    <time_frame>Session 5 (48 Wks) - 4 weeks post-injection compared to baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Assessment Scale (TAS), Approx Wk 60 + 4 Wks Post-injection Compared to Baseline. Rating of Cervical Dystonia Symptoms</measure>
    <time_frame>Session 6 (60 Wks) - 4 weeks post-injection compared to baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Assessment Scale (TAS), Approx Wk 72 + 4 Wks Post-injection Compared to Baseline. Rating of Cervical Dystonia Symptoms</measure>
    <time_frame>Session 7 (72 Wks) - 4 weeks post-injection compared to baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Assessment Scale (TAS), Approx Wk 84 + 4 Wks Post-injection Compared to Baseline. Rating of Cervical Dystonia Symptoms</measure>
    <time_frame>Session 8 (84 Wks) - 4 weeks post-injection compared to baseline</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">502</enrollment>
  <condition>Cervical Dystonia</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Botulinum Toxin Type B</intervention_name>
    <description>Eligible patients could receive injections of MYOBLOC once every 12 weeks. Total Dose could range from 5,000 Units up to 25,000 Units.</description>
    <other_name>MYOBLOC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older

          -  body weight of at least 46 kilograms

          -  History of Cervical Dystonia of at least one year's duration who in the opinion of the
             Investigator requires treatment

        Exclusion Criteria:

          -  Inability to give informed consent

          -  Patient who has been previously treated with botulinum Toxin Type B

          -  Patient who has received a Botulinum toxin Type A injection in the last 12 weeks.

          -  History of phenol injections involving the neck or shoulder region in the last 12
             months.

          -  Patients with neck contractures or cervical spine disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2008</study_first_submitted>
  <study_first_submitted_qc>June 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2008</study_first_posted>
  <results_first_submitted>May 12, 2009</results_first_submitted>
  <results_first_submitted_qc>August 13, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 23, 2009</results_first_posted>
  <last_update_submitted>September 22, 2009</last_update_submitted>
  <last_update_submitted_qc>September 22, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 2, 2009</last_update_posted>
  <responsible_party>
    <name_title>Sharon Reinhard, MS, Associate Director, Clinical Development</name_title>
    <organization>Solstice Neurosciences, Inc</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dystonia</mesh_term>
    <mesh_term>Dystonic Disorders</mesh_term>
    <mesh_term>Torticollis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
    <mesh_term>rimabotulinumtoxinB</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Approximately 500 subjects were recruited from 36 centers in North America.</recruitment_details>
      <pre_assignment_details>Subjects had to be Botulinum Toxin Type B naive and could not have received a Botulinum Toxin Type A treatment within 12 weeks of enrollment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>MYOBLOC Open Label Treatment</title>
          <description>All patients meeting enrollment criteria received open-label MYOBLOC. Patients were eligible for repeat injections approximately every 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>MYOBLOC Treatment Session 1 (Time 0)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="502"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="495">Approximately 70% of subjects completed at least 2 years of treatment.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>MYOBLOC Treatment Session 2 (App 12 Wks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="495"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="475"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>MYOBLOC Treatment Session 3 (App 24 Wks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="475"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="450"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>MYOBLOC Treatment Session 4 (App 36 Wks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="450"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="428"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>MYOBLOC Treatment Session 5 (App 48 Wks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="428"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="396"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>MYOBLOC Treatment Session 6 (App 60 Wks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="396"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="377"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>MYOBLOC Treatment Session 7 (App 72 Wks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="377"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="353"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>MYOBLOC Treatment Session 8 (App 84 Wks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="353"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="329"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MYOBLOC Open Label Treatment</title>
          <description>All patients meeting enrollment criteria received open-label MYOBLOC. Patients were eligible for repeat injections approximately every 12 weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="502"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="419"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="341"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>North America</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="502"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Treatment Assessment Scale (TAS), 4 Wks Post-injection Compared to Baseline (Time 0), Rating of Cervical Dystonia Symptoms</title>
        <description>7 point rating scale (-3 = significantly worse, 0 = no change, +3 = significantly better. Comparison at Wk 4 to baseline. Rating of Cervical Dystonia Symptoms</description>
        <time_frame>Session 1 - Time 0, 4 weeks post-injection compared to baseline</time_frame>
        <population>Safety Population/Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>MYOBLOC Open Label Treatment</title>
            <description>All patients meeting enrollment criteria received open-label MYOBLOC. Patients were eligible for repeat injections approximately every 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Assessment Scale (TAS), 4 Wks Post-injection Compared to Baseline (Time 0), Rating of Cervical Dystonia Symptoms</title>
          <description>7 point rating scale (-3 = significantly worse, 0 = no change, +3 = significantly better. Comparison at Wk 4 to baseline. Rating of Cervical Dystonia Symptoms</description>
          <population>Safety Population/Intent to Treat</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="495"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="0.1" lower_limit="-3" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Assessment Scale (TAS), Approx Wk 12 + 4 Wks Post-Injection Compared to Baseline. Rating of Cervical Dystonia Symptoms</title>
        <description>7 point rating scale (-3=significantly worse, 0=no change, +3=significantly better), comparison of Wk 12 + 4, compared to baseline. Rating of Cervical Dystonia Symptoms</description>
        <time_frame>Session 2 (12 wks) - 4 weeks post-injection compared to baseline</time_frame>
        <population>safety population/Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>MYOBLOC Open Label Treatment</title>
            <description>All patients meeting enrollment criteria received open-label MYOBLOC. Patients were eligible for repeat injections approximately every 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Assessment Scale (TAS), Approx Wk 12 + 4 Wks Post-Injection Compared to Baseline. Rating of Cervical Dystonia Symptoms</title>
          <description>7 point rating scale (-3=significantly worse, 0=no change, +3=significantly better), comparison of Wk 12 + 4, compared to baseline. Rating of Cervical Dystonia Symptoms</description>
          <population>safety population/Intent to Treat</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="475"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Assessment Scale (TAS), Approx Wk 24 + 4 Wks Post-injection Compared to Baseline. Rating of Cervical Dystonia Symptoms</title>
        <description>7 point scale (-3=significantly worse, 0=no change, +3=significantly better). Comparison of Wk 24 + 4, compared to baseline. Rating of Cervical Dystonia Symptoms</description>
        <time_frame>Session 3 (24 Wks) - 4 weeks post-injection compared to baseline</time_frame>
        <population>safety population/Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>MYOBLOC Open Label Treatment</title>
            <description>All patients meeting enrollment criteria received open-label MYOBLOC. Patients were eligible for repeat injections approximately every 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Assessment Scale (TAS), Approx Wk 24 + 4 Wks Post-injection Compared to Baseline. Rating of Cervical Dystonia Symptoms</title>
          <description>7 point scale (-3=significantly worse, 0=no change, +3=significantly better). Comparison of Wk 24 + 4, compared to baseline. Rating of Cervical Dystonia Symptoms</description>
          <population>safety population/Intent to Treat</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="450"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Assessment Scale (TAS), Approx Wk 36 + 4 Wks Post-injection Compared to Baseline. Rating of Cervical Dystonia Symptoms</title>
        <description>7 point scale (-3=significantly worse, 0=no change, +3=significantly better). Comparison of Wk 36 + 4, compared to baseline. Rating of Cervical Dystonia Symptoms</description>
        <time_frame>Session 4 (36 Wks) - 4 weeks post-injection compared to baseline</time_frame>
        <population>safety population/Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>MYOBLOC Open Label Treatment</title>
            <description>All patients meeting enrollment criteria received open-label MYOBLOC. Patients were eligible for repeat injections approximately every 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Assessment Scale (TAS), Approx Wk 36 + 4 Wks Post-injection Compared to Baseline. Rating of Cervical Dystonia Symptoms</title>
          <description>7 point scale (-3=significantly worse, 0=no change, +3=significantly better). Comparison of Wk 36 + 4, compared to baseline. Rating of Cervical Dystonia Symptoms</description>
          <population>safety population/Intent to Treat</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Assessment Scale (TAS), Approx Wk 48 + 4 Wks Post-injection Compared to Baseline. Rating of Cervical Dystonia Symptoms</title>
        <description>7 point scale (-3=significantly worse, 0=no change, +3=significantly better). Comparison of Wk 48 + 4, compared to baseline. Rating of Cervical Dystonia Symptoms</description>
        <time_frame>Session 5 (48 Wks) - 4 weeks post-injection compared to baseline</time_frame>
        <population>Safety Population/Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>MYOBLOC Open Label Treatment</title>
            <description>All patients meeting enrollment criteria received open-label MYOBLOC. Patients were eligible for repeat injections approximately every 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Assessment Scale (TAS), Approx Wk 48 + 4 Wks Post-injection Compared to Baseline. Rating of Cervical Dystonia Symptoms</title>
          <description>7 point scale (-3=significantly worse, 0=no change, +3=significantly better). Comparison of Wk 48 + 4, compared to baseline. Rating of Cervical Dystonia Symptoms</description>
          <population>Safety Population/Intent to Treat</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="396"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="0.1" lower_limit="-3" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Assessment Scale (TAS), Approx Wk 60 + 4 Wks Post-injection Compared to Baseline. Rating of Cervical Dystonia Symptoms</title>
        <description>7 point scale (-3=significantly worse, 0=no change, +3=significantly better). comparison Wk 60 + 4, compared to baseline. Rating of Cervical Dystonia Symptoms</description>
        <time_frame>Session 6 (60 Wks) - 4 weeks post-injection compared to baseline</time_frame>
        <population>Safety Population/Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>MYOBLOC Open Label Treatment</title>
            <description>All patients meeting enrollment criteria received open-label MYOBLOC. Patients were eligible for repeat injections approximately every 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Assessment Scale (TAS), Approx Wk 60 + 4 Wks Post-injection Compared to Baseline. Rating of Cervical Dystonia Symptoms</title>
          <description>7 point scale (-3=significantly worse, 0=no change, +3=significantly better). comparison Wk 60 + 4, compared to baseline. Rating of Cervical Dystonia Symptoms</description>
          <population>Safety Population/Intent to Treat</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="377"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Assessment Scale (TAS), Approx Wk 72 + 4 Wks Post-injection Compared to Baseline. Rating of Cervical Dystonia Symptoms</title>
        <description>7 point scale (-3=significantly worse, 0=no change, +3=significantly better). Comparison Wk 72 + 4, compared to baseline. Rating of Cervical Dystonia Symptoms</description>
        <time_frame>Session 7 (72 Wks) - 4 weeks post-injection compared to baseline</time_frame>
        <population>Safety Population/Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>MYOBLOC Open Label Treatment</title>
            <description>All patients meeting enrollment criteria received open-label MYOBLOC. Patients were eligible for repeat injections approximately every 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Assessment Scale (TAS), Approx Wk 72 + 4 Wks Post-injection Compared to Baseline. Rating of Cervical Dystonia Symptoms</title>
          <description>7 point scale (-3=significantly worse, 0=no change, +3=significantly better). Comparison Wk 72 + 4, compared to baseline. Rating of Cervical Dystonia Symptoms</description>
          <population>Safety Population/Intent to Treat</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="353"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Assessment Scale (TAS), Approx Wk 84 + 4 Wks Post-injection Compared to Baseline. Rating of Cervical Dystonia Symptoms</title>
        <description>7 point scale (-3=significantly worse, 0=no change, +3=significantly better). Comparison Wk 84 + 4, compared to baseline. Rating of Cervical Dystonia Symptoms</description>
        <time_frame>Session 8 (84 Wks) - 4 weeks post-injection compared to baseline</time_frame>
        <population>Safety Population/Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>MYOBLOC Open Label Treatment</title>
            <description>All patients meeting enrollment criteria received open-label MYOBLOC. Patients were eligible for repeat injections approximately every 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Assessment Scale (TAS), Approx Wk 84 + 4 Wks Post-injection Compared to Baseline. Rating of Cervical Dystonia Symptoms</title>
          <description>7 point scale (-3=significantly worse, 0=no change, +3=significantly better). Comparison Wk 84 + 4, compared to baseline. Rating of Cervical Dystonia Symptoms</description>
          <population>Safety Population/Intent to Treat</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="329"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>MYOBLOC Open Label Treatment</title>
          <description>All patients meeting enrollment criteria received open-label MYOBLOC. Patients were eligible for repeat injections approximately every 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Coronary Syndrome</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Angina</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>AV Block 2nd Degree</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Coronary Artery Occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>sinus bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>adrenal insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>eye haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal adhesions</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>celiac disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>diverticulum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>dysphagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>GI hemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>GI Reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>inguinal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>inguinal hernia obsstructive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>small intestine obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>upper GI hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>chest discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>chest pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>facial pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>non cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>bile duct stone</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>cholecystitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>cholelithiasis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>hepatorenal syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>jaundice</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>abdominal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>arthritis infective</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>bartholin abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>GI norwalk virus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>GI viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>haemophilis infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>pelvic abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>post operative abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>pyelonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Infection (URI)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection (UTI)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>vaginal cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>drug toxicitiy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>accidental overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>brain contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>clavicle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>hip fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>incisional hernia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>medication error</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>multiple fractures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>overdose</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>post procedural nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>post pocedural vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>post operative ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>road traffic accident</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>subdural hematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>upper limb fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>oxygen saturation decrease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>dehydration</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>back disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>intervebral disc degeneration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>intervebral disc protrusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>muscle spasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>osteoarthritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>torticollis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>basal cell carcinoma</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>basosquamous carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>benign ovarian tumor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>bone neoplasm malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>brain neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>breast cancer</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>keratocanthoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>malignant neoplasm progression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>prostate cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>skin cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>uterine leiomyoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>vulval cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular Accident (CVA)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>cervical myelopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>convulsion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>dystonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>epilepsy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>intracranial aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>mutiple sclerosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>vertebrobasilar insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>pregnancy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>confusional state</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>depression</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>dissociative identity disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>major depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>suicidal ideation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>bladder prolapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>renal failure acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>stress incontinence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>cystocele</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>endometriosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>menorrhagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>ovarian cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>ovarian cyst rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title vocab="MdDRA">pelvic peritoneal adhesions</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>rectocele</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>atelectasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>choking</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title vocab="MEdDRA">Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>dyspnea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>pulmonary embolism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>pulmonary edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>sleep apnea syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>blood pressure fluctuation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>haemotoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="494"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>vertigo</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>hypothyroidism</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>cataract</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>conjunctivitis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>dry eye</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>vision blurred</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>abdominal pain upper</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title vocab="MeddRA">constipation</sub_title>
                <counts group_id="E1" events="43" subjects_affected="43" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="48" subjects_affected="48" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>dry mouth</sub_title>
                <counts group_id="E1" events="348" subjects_affected="348" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>dyspepsia</sub_title>
                <counts group_id="E1" events="48" subjects_affected="48" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>dysphagia</sub_title>
                <counts group_id="E1" events="203" subjects_affected="203" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>GERD</sub_title>
                <counts group_id="E1" events="42" subjects_affected="42" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="72" subjects_affected="72" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title vocab="MdDRA">toothache</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="30" subjects_affected="30" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>asthenia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>chest pain</sub_title>
                <counts group_id="E1" events="28" subjects_affected="28" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="51" subjects_affected="51" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>influenza like illness</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>injection site pain</sub_title>
                <counts group_id="E1" events="114" subjects_affected="114" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>injection site reaction</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>edema peripheral</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>pyrexia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>bronchitis</sub_title>
                <counts group_id="E1" events="50" subjects_affected="50" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>cystitis</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>ear infection</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>fungal infection</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>GI viral</sub_title>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>herpes zoster</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>influenza</sub_title>
                <counts group_id="E1" events="84" subjects_affected="84" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>nasopharyngitis</sub_title>
                <counts group_id="E1" events="110" subjects_affected="110" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>otitis media</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>sinusitis</sub_title>
                <counts group_id="E1" events="68" subjects_affected="68" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>tooth abscess</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" events="70" subjects_affected="70" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>joint sprain</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>muscle sprain</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>overdose</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>procedural pain</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>road traffic accident</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>blood cholesterol increased</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hypercholesterolemia</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>arthralgia</sub_title>
                <counts group_id="E1" events="61" subjects_affected="61" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>arthritis</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>back pain</sub_title>
                <counts group_id="E1" events="77" subjects_affected="77" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>intervertebral disc degeneration</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>interverterbral disc protrusion</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>muscle spasm</sub_title>
                <counts group_id="E1" events="77" subjects_affected="77" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>muscle tightness</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>muscle weakness</sub_title>
                <counts group_id="E1" events="41" subjects_affected="41" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>musculoskeletal weakness</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>myalgia</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>neck pain</sub_title>
                <counts group_id="E1" events="32" subjects_affected="32" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>osteoarthritis</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>pain in extremity</sub_title>
                <counts group_id="E1" events="56" subjects_affected="56" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>shoulder pain</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>tendonitis</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>torticollis</sub_title>
                <counts group_id="E1" events="170" subjects_affected="170" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>balance disorder</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>carpal tunnel syndrome</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="68" subjects_affected="68" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>head titubation</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="117" subjects_affected="117" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>hypoaesthesia</sub_title>
                <counts group_id="E1" events="46" subjects_affected="46" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>paraesthesia</sub_title>
                <counts group_id="E1" events="31" subjects_affected="31" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>syncope</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>tremor</sub_title>
                <counts group_id="E1" events="33" subjects_affected="33" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>anxiety</sub_title>
                <counts group_id="E1" events="36" subjects_affected="36" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>depression</sub_title>
                <counts group_id="E1" events="67" subjects_affected="67" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" events="46" subjects_affected="46" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>stress</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>choking</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" events="51" subjects_affected="51" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>dry throat</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>dysphonia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>dyspnea</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>nasal congestion</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>pharangolaryngeal pain</sub_title>
                <counts group_id="E1" events="36" subjects_affected="36" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>pruritis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="502"/>
              </event>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" events="31" subjects_affected="31" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" events="43" subjects_affected="43" subjects_at_risk="502"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>No individual PI can disclose results until after a group manuscript is published.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sharon Reinhard, M.S, Associate Director, Clinical Development</name_or_title>
      <organization>Solstice Neurosciences, Inc</organization>
      <phone>267-620-8083</phone>
      <email>Sharon.Reinhard@solsticeneuro.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

